Oxford Genome Sciences to Evaluate Bayer Diagnostics Breast Cancer Biomarkers

Mar 16, 2005

NEW YORK, March 16 (GenomeWeb News) -Oxford Genome Sciences will use its proteomics platform and its Oxford Genome Anatomy Project to evaluate biomarkers linked to breast cancer for Bayer HealthCare's diagnostics division, the companies said today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

Skipped Steps

A former Penn State Hershey Medical Center staffer has admitted to lying about skipping mandatory steps of genetic cancer tests he performed, the Associated Press reports.

Just a Few Bats

The genome of a rare, red bat suggests that its effective population size has been in decline for thousands of years, according to a PLOS One study.

This Week in Nature

In Nature this week: investigation into the genetics of medulloblastoma, and more.

Genomics for the Trees

A project in the UK is to use genomic selection to speed spruce tree growth, according to Innovators Magazine.

Main menu